GPX4 and neoplasm: Therefore, the development of safer, tumor-selective GPX4 inhibitors or nanoparticle-based delivery systems for RSL3, in conjunction with existing therapies, may be necessary to effectively harness ferroptosis in therapy-resistant HNC.